HU-211/ DEXANABINOL/ ETS-2101 – synthetic, CB 2 agonist


A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat.                                               (abst – 1993)


HU-211, a Novel Noncompetitive N-Methyl-D-Aspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat           (full – 1995)                                          


45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211.                                                                    (abst – 1995)


Development of HU-211 as a neuroprotectant for ischemic brain damage.                   (abst – 1995)


A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis.        (full – 1996)                                        


HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy.                                                               (abst – 1996)


Protection Against Septic Shock and Suppression of Tumor Necrosis Factor α and Nitric Oxide Production by Dexanabinol (HU-211), a Nonpsychotropic Cannabinoid

(full – 1997)             


Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant.                                                  (abst – 1997)


Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. (abst – 1999)                                


Cannabinoids in clinical practice.                     (abst – 2000)


Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial.                                                                    (abst – 2002)


Dexanabinol: a novel cannabinoid with neuroprotective properties.                      (abst – 2003)









Dexanabinol (HU-211) has a beneficial effect on axonal sprouting and survival after rat optic nerve crush injury.                                                             (abst – 2003)


Therapeutic potential of cannabinoids in CNS disease.                    (abst – 2003)


Dexanabinol: dexanabinone, HU 211, PA 50211, PRS 211007, sinnabidol. (abst – 2003)                                


Dexanabinol prevents development of vasospasm in the rat femoral artery model. (abst – 2008)                                


Latest Studies Imply That Cannabinoids Are Protective Against Alcohol-Induced Brain Damage            (news – 2011)               


Cannabinoid May Treat Brain Cancer                      (news – 2012)



Clinical trial evaluates synthetic cannabinoid as brain cancer treatment                       (news – 2012)

Share a link for